Advertisement
Surgery
Advanced searchSave search
Research Article| Volume 116, ISSUE 6, P1118-1122, December 1994

Scintiscans and carcinoid tumors

DOI:https://doi.org/10.5555/uri:pii:0039606094903131
Scintiscans and carcinoid tumors
Previous ArticleHepatic arterial chemoembolization for metastatic neuroendocrine tumors
Next ArticleApparent lymph node primary gastrinoma
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background. The presence of somatostatin receptors on carcinoid tumors mediates imaging of tumor extent and inhibition of tumor growth and marker secretion. This prospective study aimed to evaluate radiolabeled somatostatin analog scans in the therapeutic workup of carcinoids.
      Methods. Twenty-one patients with carcinoids underwent 26 scans with iodine octreotide or indium pentetreotide. The results for tumor and metastases imaging were analyzed and compared with those of a short inhibition test of marker secretion and with those of metaiodobenzylguanidine scan.
      Results. The sensitivity for obtaining images of the overall 43 tumor sites was 72%. We had no false-positive results. Unknown tumor sites were discovered in three patients. The results were slightly better with indium pentetreotide and metastases imaging. A positive scan did not always preclude responsiveness to the functional effect of octreotide. Results of somatostatin analog scans were better than those with metaidobenzylguanidine. The two techniques were complementary- in one patient.
      Conclusions. The choice of treatment for patients with carcinoid tumors should benefit from functional inhibition test with octreotide and from indium pentetreotide and metaidobenzylguanidine scans.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Arnold R.
        • Neuhaus C.
        • Benning R.
        • et al.
        Somatostatin analogue Sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.
        World J Surg. 1993; 17: 511-519
        • Chanson P.
        • Timsit J.
        • Harris A.
        Octréotide, analogue de la Somatostatine. Propriétés pharmacologiques et applications thér-apeutiques dans les tumeurs endocrines hypophysaires.
        Presse MM. 1993; 22: 2009-2016
        • Patel Y.
        General aspects of the biology and function of Somatostatin.
        in: Basic and clinical aspects of neuroscience. Vol 4. Springer-Sandoz, Paris1992: 1-16
        • Krenning E.
        • Kwekkeboom D.
        • Bakker W.
        • et al.
        Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-Octreotide: the Rotterdam experience with more than 1000 patients.
        Eur J Nuc Med. 1993; 20: 716-731
        • Sassolas G.
        • Mabille L.
        • Houzard C.
        La Somatostatine: du récepteur à la scintigraphie.
        Revue Française de Gastro-entér-ologie. 1994; 30: 373-376
        • Lamberts S.
        • Krenning E.
        • Reubi J.
        The role of Somatostatin and its analogues in the diagnosis and treatment of tumors.
        Endocr Rev. 1991; 12: 450-482
        • Bomanji J.
        • Mather S.
        • Ur E.
        • Grossman A.
        • Besser G.M.
        • Britton K.
        Imaging Somatostatin receptor-positive neoplasms with 1231 Tyr-3-Octreotide (TOOT) and 111In [DTPA-D-Phe1]-Oc-treotide (DOLT) Somatostatin analogues.
        J Nucl Med. 1992; 33: 914
        • Dorr U.
        • Rath U.
        • Sautter-Bihl M.L.
        • et al.
        Improved visualisation of carcinoid liver metastases by indium-111 Pentetreotide scintigraphy following treatment with cold Somatostatin analogue.
        Eur J Nucl Med. 1993; 20: 431-433
        • Kvols L.
        Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors.
        Gastroenterology. 1993; 105: 1909-1914
        • Hoefnagel C.
        Radionuclide therapy revisited.
        Eur J Nucl Med. 1991; 18: 408-431
        • Racadot N.
        • Rousseaux J.
        • Dautrevaux M.
        Methode directe de dosage du 5-HIAA urinaire par HPLC: 6° colloque sur les Actualités en immunoanalyse.
        in: Bioclinord, Lille, France1989: 233
        • Nocaudie N.
        • Huglo D.
        • Deveaux M.
        • Carnaille B.
        • Proye C.
        • Marchandise X.
        Iodine- 123-Tyr-3-Octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by Octreotide.
        J Noel Med. 1994; 35: 57-62
        • Weinel R.
        • Neuhaus C.
        • Stapp J.
        • et al.
        Preoperative localization of gastrointestinal endocrine tumors using Somatostatin-receptor scintigraphy.
        Ann Surg. 1993; 218: 640-645
        • Kvols L.
        • Reubi J.
        • Horisberger U.
        • Moertel C.
        • Rubin J.
        • Charboneau J.
        The presence of Somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to Octreotide.
        Yale J Biol Med. 1992; 65: 505-518
        • Kwekkeboom D.
        • Krenning E.
        • Bakker W.
        • Oei H.
        • Kooij P.
        • Lamberts S.
        Somatostatin analogue scintigraphy in carcinoid tumors.
        Eur J Nucl Med. 1993; 20: 283-292
        • Kwekkeboom D.
        • Assiest J.
        • Hofland L.
        • Reubi J.
        • Lamberts S.
        • Krenning E.
        A case of antibody formation against Octreotide visualised with 111In-Octreotide scintigraphy.
        Clin Endocrinol. 1993; 39: 239-244
        • Joensuu H.
        • Katka K.
        • Kujari H.
        Dramatic response of a metastatic carcinoid tumor to a combination of interferon and Octreotide.
        Acta Endocrinol. 1992; 126: 184-185
        • Van Dongen A.
        • Veroeff N.
        • Bemelman F.
        • Van Royen E.
        Somatostatin receptor imaging with 111In-Pentatreotide for whole body studies and high resolution brain SPELT.
        Eur J Nucl Med. 1992; 19: 679
        • Ivancevic V.
        • Nauck C.
        • Sandrock D.
        • et al.
        Somatostatin receptor scintigraphy with 111In-Pentatreotide in gastroenteropancreatic endocrine tumors (GEP).
        Eur J Nucl Med. 1992; 19: 736
        • Kvols L.
        • Brown M.
        • O'Connor M.
        • et al.
        Evaluation of a radiolabeled Somatostatin analogue (I-123 Octreotide) in the detection and localization of carcinoid and islet tumors.
        Radiology. 1993; 187: 129-133
        • Carcinoïdes Boissel P.
        Proye C. Dubost C. Endocrinologie Chirurgicale. Medsi/Macgraw-Hill, Paris1991: 217-241

      Article info

      Footnotes

      ☆Presented at the Fifteenth Annual Meeting of the American Association of Endocrine Surgeons, Dearborn, Mich., April 17–19, 1994.

      Identification

      DOI: https://doi.org/10.5555/uri:pii:0039606094903131

      Copyright

      © 1994 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX